Literature DB >> 16598621

[Functional capacity as a criterion for patient selection--too poor or too good for CRT?].

M Schlegl1, C Butter.   

Abstract

The article analyses the status of functional tests used in patient selection for cardiac resynchronization therapy (CRT). Based on published randomized trials, the NYHA classification, the quality of life score, the 6-minute walk and the cardio-pulmonary exercise test (CPX) are reviewed. The NYHA classification is a weak and unspecific test and should be used only as a basic consideration in patient selection. The 6-minute walk test shows a wide spread of values and high dependency on patients' motivation. Patients' functional capacity is measured most objectively by the CPX test, which additionally stratifies prognosis. We conclude that functional capacity is an important criterion in patient selection for CRT. However, primary functional status is of minor importance in estimating the expected functional benefit since multiple factors influence the success of CRT.

Entities:  

Mesh:

Year:  2006        PMID: 16598621     DOI: 10.1007/s00399-006-1107-7

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  30 in total

1.  Guidelines for the diagnosis and treatment of chronic heart failure.

Authors:  W J Remme; K Swedberg
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

2.  Cardiac resynchronization in chronic heart failure.

Authors:  William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

3.  [Policy paper to the cardiac re-sychronization therapy].

Authors:  C Stellbrink; A Auricchio; B Lemke; W von Scheidt; J Vogt; R Dietz; M Gottwik; B Levenson; T Meinertz; A Osterpey; U Tebbe; R H Strasser; K Werdan; G Arnold; D Behrenbeck; E Fleck; H J Trappe
Journal:  Z Kardiol       Date:  2003-01

4.  [Guidelines for heart pacemaker therapy].

Authors:  B Lemke; B Nowak; D Pfeiffer
Journal:  Z Kardiol       Date:  2005-10

5.  Exercise performance following cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay.

Authors:  Angelo Auricchio; Michael Kloss; Silke Isabelle Trautmann; Susanne Rodner; Helmut Klein
Journal:  Am J Cardiol       Date:  2002-01-15       Impact factor: 2.778

Review 6.  [Effect of cardiac resynchronization therapy (CRT) on exercise tolerance, functional capacity and quality of life in patients with congestive heart failure].

Authors:  C Butter
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2005-03

7.  Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy.

Authors:  Maria Vittoria Pitzalis; Massimo Iacoviello; Roberta Romito; Pietro Guida; Elisabetta De Tommasi; Giovanni Luzzi; Matteo Anaclerio; Cinzia Forleo; Paolo Rizzon
Journal:  J Am Coll Cardiol       Date:  2005-01-04       Impact factor: 24.094

Review 8.  [Echocardiography in cardiac resynchronization therapy: identification of suitable patients, follow-up and therapy optimization].

Authors:  Ole-Alexander Breithardt; Anil Martin Sinha; Andreas Franke; Peter Hanrath; Christoph Stellbrink
Journal:  Herz       Date:  2003-11       Impact factor: 1.443

9.  Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure.

Authors:  J Myers; L Gullestad; R Vagelos; D Do; D Bellin; H Ross; M B Fowler
Journal:  Ann Intern Med       Date:  1998-08-15       Impact factor: 25.391

10.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.